A story in U.K. newspaper The Telegraph says Johnson & Johnson employees were not only aware of problems with its ASR hip implant for years before the device’s 2010 recall, but actively discussed manipulating data to conceal those problems.
Studies show that nearly half of the implants, made by Johnson & Johnson subsidiary DePuy Orthopaedics, break down and need replacement after only a few years. They also have a tendency to ...
continue reading...
State officials in Massachusetts have shut down 11 specialty pharmacies of the type responsible for last year’s deadly meningitis outbreak, following a series of surprise inspections.
According to a story in USA Today, inspectors looked in on 40 compounding pharmacies, which produce custom prescriptions in response to specific physician orders.
Compounding pharmacies aren’t subject to the same regulations as other pharmaceutical manufacturers.
That regulatory gap drew attention last year, ...
continue reading...
According to a story in the New York Times, Merck is delaying its attempts to get approval for an experimental osteoporosis drug called odanacatib, because it is seeking additional data from a clinical trial. That announcement helped send the company’s shares down 3 percent.
The story says Merck reported that it earned $1.4 billion, or 46 cents a share, in the fourth quarter. That compares with $1.51 billion, or 49 cents ...
continue reading...
An editorial in the New York Times takes Johnson & Johnson subsidiary DePuy Orthopaedics to task for apparently sitting on evidence that a line of its hip implants posed a danger to patients.
“Though the company says the evidence will ultimately show that it acted appropriately, it clearly has a lot of explaining to do,” the editorial says.
The model in question ...
continue reading...
During a trial centering on Johnson & Johnson’s ASR hip implants, Bloomberg reports, a biomedical engineering expert told the jury that the devices had multiple design flaws.
Johnson & Johnson recalled the all-metal implants, manufactured by subsidiary DePuy Orthopaedics, in 2010. At the time, the company said 12 percent fail within five years. Subsequent studies found that nearly half of them ...
continue reading...
A piece in The Economist deals with the negative information coming out in Johnson & Johnson’s trial over ASR hip implants manufactured by its subsidiary, DePuy Orthopaedics.
“Most companies do everything they can to keep their executives away from court,” the piece states. “A case in California helps to demonstrate why.”
Studies have shown nearly half of the implants break down and ...
continue reading...
